In this study, two de novo libraries focused on the epigenetic target DNMT1 were designed with 5575 and 2491 compounds, respectively. The larger library was created with AlvaBuilder, a ligand-based program, while the other was constructed with LigBuilder, software based on protein structure. The number of compounds was smaller since the structure-based strategy took more time and computational resources.